InnoFly BioCenter

Our mission:

To support the Austrian life science scene in creating the necessary framework conditions for successful R&D. These framework conditions can relate to suitable laboratory and office infrastructure as well as expertise in the form of consulting.

Life Sciences

Life science is an essential pillar of our global society.
In addition to combating climate change and a sustainable and
environmentally friendly energy supply, life science is
the central topic of our society. This has been made even
clearer by the COVID-19 crisis of recent years.

Biotechnology
Physics
Chemistry
Analytics
Medical technology
Pharmacy
Diagnostics

In international scientific parlance, life sciences are scientific research directions with a strong interdisciplinary orientation, which are mainly concerned with the application of scientific findings from modern biology (including biotechnology), chemistry, physics, analytics and medicine as well as related fields.

The life science industry in Austria continues to show solid development despite the impact of the Russian attack on Ukraine on investments. Companies in areas such as biotechnology, pharmaceuticals and medical technology are continuing their innovation projects and looking for ways to strengthen their competitiveness.

For the successful implementation of life science companies, 4 factors are essential:

Solid innovation potential

Austrian universities and research institutes in the field of life sciences are internationally successful.

There are many research groups that conduct research at a high level and are constantly generating innovations.

The Austrian environment thus offers an excellent basis for the successful development of strong life science companies.

Entrepreneurship

Entrepreneurship in the Austrian life science industry is flourishing due to a growing number of startups and innovators in areas such as biotechnology, medical technology and pharma.

Despite challenges such as limited venture capital and suitable laboratory space, the government is deploying specific funding programs and investment incentives to support the growth of these startups and drive the development of new therapies.

Austria is increasingly perceived as an innovation hub in this sector, indicating an increase in biotechnology companies in recent years. That is why it is important to us at InnoFly BioCenter to support potential life science entrepreneurs.

Personnel and space resources

Austrian universities, universities of applied sciences, technical colleges, technical colleges and companies in the life sciences sector train highly qualified personnel.

In particular, innovators and startups usually search intensively for space to implement their ideas. The demand for available laboratory and office space often exceeds supply. This applies in particular to flexible laboratory space that can be shared with other companies (coworking spaces).

In order to promote the growth of young companies and strengthen their ability to innovate, InnoFly BioCenter supports in creating the necessary framework conditions. These framework conditions can relate to suitable laboratory and office infrastructure as well as expertise in the form of consulting.

Venture capital & funding

Access to venture capital and government funding for biotechnology companies and startups in Austria is crucial to support growth and innovation in the sector. Government support programmes usually require a significant proportion of external venture capital as a prerequisite for financing. Unfortunately, there is currently too little venture capital for the life sciences sector in Austria, which often prevents access to funding programmes.

The InnoFly Group has a great deal of experience with government funding programmes and with raising external venture capital. We are happy to use this experience to support innovative startups.

We at InnoFly BioCenter can help you find suitable laboratories, cleanrooms, and offices according to your needs.

Room to grow

Space available

Laboratory building I
Vienna

Since summer 2023, InnoFly BioCenter GmbH has been leasing a total of approx. 1200 m2 of laboratory and office space over two floors in the Biotech Competence Center (BCC) at Leberstraße 20, 1110 Vienna. These areas are currently shared by biotechnology and service companies, such as Evercyte GmbH, TAmiRNA GmbH, InnoFly Management GmbHRockFish Bio AG and Competence Center CHASE GmbH.

In these two floors, 52 m2 of laboratory ancillary / storage rooms, as well as 98 m2 of office space are currently available. On the 6th floor there are another 5 large and 2 small laboratories, as well as 5 laboratory ancillary rooms with a total area of 397 m2 and 5 offices with a total of 71 m2, as well as common areas (toilets, social room, etc.) with 133 m2 available.

Interested? Please contact us!

Laboratory building II
Vienna

Start of construction postponed

According to the current developer, this project is delayed but is currently being examined by several interested real estate developers. As soon as there is a new date for the start of construction, it will be communicated here.

Laboratory building III
Linz

Needs assessment

One member of the InnoFly group of companies – Phoenestra GmbH – is active in Linz and plans to build infrastructure in the coming years. Concrete plans are currently underway with a real estate developer for a laboratory building project that is to be built centrally in Linz. We are currently looking for other companies from the fields of life sciences, medical technology, etc. that are interested in space in the greater Linz area.

Contact us!

The InnoFly BioCenter Team

Dirk B. Strickmann

Dirk Strickmann has more than 20 years of experience in the pharmaceutical industry/biotechnology (ABRI Vienna, Novartis/Sandoz & Nabriva Therapeutics GmbH) in various positions with a strong scientific background as a chemist and bioanalyst, covering all phases of drug development from initial synthesis through the various preclinical and clinical development phases to regulatory submissions. He can also look back on 7 years of experience as Managing Director of Nabriva Therapeutics GmbH.

The InnoFly BioCenter location at Leberstraße 20, 1110 Vienna, was significantly designed by Dirk Strickmann. In July 2024, Otto Kanzler handed over the management of InnoFly BioCenter to Dirk Strickmann.

Otto Kanzler

Due to his extensive and decades of experience in process development and business development in the field of biotechnology, Otto Kanzler has become a sought-after and successful management consultant. Since 2007, he has been working as an independent management consultant for production and technology development in the biotechnology and pharmaceutical industries with a focus on strategic and economic issues.

Otto Kanzler is a co-founder, board member, CEO and/or CFO of several biotech companies in Austria. From 1993 to 2007, he was Head of Department at Boehringer Ingelheim Austria. He was responsible for the economic issues of the biopharmaceutical industry. Previously, he was Head of Process Development for Biopharmaceutical Processes at Boehringer Ingelheim Austria (1981 – 1993).

Erich Jaklitsch

During his more than 25 years of experience in all areas of accounting, Erich Jaklitsch acquired profound and versatile technical know-how. After 10 years of working in various SMEs, he has been an independent accountant since 2001 and a self-employed accountant since 2009, specializing in service companies and innovative spin-offs.

Erich Jaklitsch is co-founder and CEO of InnoFly Management GmbH. In this role, he is responsible for the ongoing accounting, balancing and tax optimisation of our clients and acts at the interface with authorities and external partners.

Klaus Graumann

Klaus Graumann brings more than 20 years of experience in the biopharmaceutical industry (Boehringer Ingelheim (Austria) and Novartis) and has been involved in the development of more than 10 now commercial biopharmaceuticals in various local and global leadership positions. Since mid-2018, he has been active as a start-up founder with a focus on stem cell technologies (Phoenestra GmbH) and as a management consultant in the field of biotechnology (CMC).